Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 19/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 19/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Revizinone SCHEMBL9584593 | 0.87 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Revizinone SCHEMBL7297062 | 0.87 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Revizinone SCHEMBL29557974 | 0.87 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Revizinone SCHEMBL7289525 | 0.87 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9583372 | 0.78 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9584441 | 0.78 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9583358 | 0.78 | PDE3B (0.70) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9584335 | 0.78 | PDE3B (0.72) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9584347 | 0.78 | PDE3B (0.72) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Water SCHEMBL9583863 | 0.78 | PDE3B (0.71) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 778 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196821-A2 | TARGETING NEUROPOD CELL GUCY2C TO CONTROL VISCERAL PAIN AND APPETITE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-10-12 | — | — | WO | claimed |
| EP-3532008-A1 | TREATMENT OF GYNOID LIPODYSTROPHY | Merz Pharma GmbH & Co. KGaA (DE) | 2019-09-04 | — | — | EP | claimed |
| WO-2019164836-A1 | SYSTEMS AND METHODS FOR COMBINED COSMETIC TREATMENT OF CELLULITE WITH ULTRASOUND | ULTHERA, INC. (US) | 2019-08-29 | — | — | WO | claimed |
| US-20190240253-A1 | TREATMENT OF GYNOID LIPODYSTROPHY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2019-08-08 | — | — | US | claimed |
| WO-2018077825-A1 | TREATMENT OF GYNOID LIPODYSTROPHY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2018-05-03 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-06-16 | — | — | US | claimed |
| WO-2005018563-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A PHOSPHODIESTERASE INHIBITOR FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | claimed |
| EP-1370211-A4 | CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | claimed |
| EP-1370211-A2 | CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS | Bristol-Myers Squibb Company (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030069169-A1 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | claimed |
| WO-2002069905-A2 | CO-ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONIST AND PHOSPHODIESTERASE INHIBITOR FOR TREATMENT OF CYCLIC-AMP ASSOCIATED DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240253-A1 | TREATMENT OF GYNOID LIPODYSTROPHY | FABP4, GYS1, EBP | PDE3B 3564/4885PDE3A 3100/4885PDE4A 2435/4885 |
| US-20030069169-A1 | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | MC4R, MC3R, MC1R | PDE3B 66/4885PDE3A 88/4885PDE4A 6/4885 |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PDE2A, PDE3B, PDE3A | PDE3B 2/4885PDE3A 3/4885PDE4A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.